9 Meters (NMTR) Rises 16.46% on June 23

Equities Staff  |

9 Meters Biopharma Inc (NASDAQ: NMTR) has risen $0.0436 (16.46%) and sits at $0.30, as of 12:05:42 est on June 23.

4,713,945 shares exchanged hands.

The Company fell 54.13% over the last 5 days and shares lost 44.62% over the last 30 days.

9 Meters anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on 9 Meters visit the company profile.

About 9 Meters Biopharma Inc

9 Meters Biopharma, Inc. ('the Company') is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

To get more information on 9 Meters Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: 9 Meters Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content